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Identity 
Other names: ARM1; EMSP; EMSP1; KLK-L1; 
MGC116827; MGC116828; Prostase; PRSS17; PSTS 
HGNC (Hugo): KLK4 
Location: 19q13.33 
Local order: Telomere to centromere. 
DNA/RNA 
Description 
The gene encompasses 4.38 kb of gDNA. 
Transcription 
Three alternative transcription start sites (TSSs)  
have been predicted or identified experimentally for the 
KLK4 gene. TSS1 was identified using 5' RACE and is 
located 639 bp upstream of TSS2, which was predicted 
using in silico analysis. TSS3 was also identified using 
5' RACE and is located 1396 bp downstream of TSS1.  
Nine KLK4 variant transcripts have been identified. 
These variants include the TSS variants, variants with 
5' UTR deletion for TSS1 and TSS2 transcripts, exon 4 
deletion and partial intron II (12bp) insertion variants, 
intron 3 insertion variants, and variants with 
combinations thereof. 
Pseudogene 
Not identified. 
 
 
 
Genomic and protein structure of the KLK4 gene. The KLK4 gene is classically comprised of 5 exons (grey boxes, classic numerals) and 
4 introns (roman numerals), although extra 5' UTR sequences in exon 1a have also been described. Shown here are the three putative 
alternative transcription start sites (TSS1, TSS2 and TSS3). Also shown are the postions of ATG1 and ATG2 that would be utilised from 
these variant transcripts. The amino acid numbering for the residues of the catalytic triad (His71, Asp116, Ser207) are relative to the full-
length protein starting from ATG1. 
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Protein 
Description 
Two KLK4 protein isoforms, full-length KLK4 (254 
amino acids) and an N-terminal truncated KLK4 (205 
amino acids) have been described. Full-length KLK4 
has a secretion signal (pre-) peptide (26 amino acids), 
followed by an activation (pro-) peptide (4 amino 
acids) and the mature chain (224 amino acids) with 1 
potential N-linked glycosylation site. The catalytic triad 
of His71, Asp116, Ser207 (relative to Met = 1 and 
encoded by ATG1 in exon 1) is conserved and is 
essential for proteolytic activity. After synthesis as a 
KLK4 full-length protein, the signal peptide is then 
cleaved and pro-KLK4 (zymogen) is subsequently 
secreted from the cell. Upon activation, the propeptide 
is removed to generate the mature active enzyme. 
KLK4 complexes with alpha(1)-antitrypsin and 
alpha(2)-antiplasmin and alpha(2)-macroglobulin. 
The N-terminal truncated KLK4 isoform initiated from 
the ATG2 in exon 2, has the pre-pro-region and 9 
amino acids from the mature KLK4 omitted, although 
the catalytic triad remains. Further, the truncated KLK4 
isoform is not glycosylated despite retaining the 
potential N-linked glycosylation site. 
Expression 
The KLK4 gene was originally designated the PRSS17 
gene and was cloned from the cells of the enamel organ 
epithelia of developing teeth in pig using degenerate 
primers encoding the EMPS1 protein. Subsequent 
studies in human tissues using Northern blot analysis 
have shown that KLK4 mRNA expression is 
predominantly localised to the prostate, although more 
sensitive RT-PCR experiments have shown that the 
breast, ovary, endometrium, salivary gland, lung, 
adrenal gland, colon, trachea, brain, testis, spinal cord, 
thyroid, skin and kidney also express KLK4 mRNA at 
low to modest levels. KLK4 mRNA has also been 
detected in sebaceous glands, sweat glands, hair 
follicles, stratum basale, stratum spinosum and stratum 
granulosum by in situ hybridisation experiments. In 
pig, KLK4 mRNA is expressed in the endometrium in 
the early stages of the oestrous cycle. 
KLK4 protein has been detected in a wide range of 
tissues at low (adrenal, aorta, brain, breast, cervix, 
heart, kidney, liver, muscle, pancreas, pituitary, 
salivary gland, small intestine, spinal cord, spleen, 
testis, skin, thyroid, and uterus) to high (prostate) 
levels. Modest levels of KLK4 protein have also been 
detected in body fluid, such as seminal plasma and 
urine. High KLK4 levels have also been detected in the 
prostate, breast and ovarian cancer tissues from 
patients. 
Localisation 
Full-length KLK4 encodes a secreted protein and is  
localised intracellularly to the cytoplasm, although GFP 
labelled N-terminal truncated isoforms have been found 
to be predominantly localised to the nucleus. 
Function 
To date, the major biological function of KLK4 has 
been derived from porcine studies which have shown 
that KLK4 is important in dental enamel mineralisation 
by degrading amelogenin, the major protein in the 
enamel matrix of developing teeth. More recently, 
KLK4 was also reported to degrade porcine enamelin 
which is another protein found in developing teeth. 
Further, in mice, KLK4 was only expressed by 
transition and maturation stage ameloblasts, which is 
consistent with KLK4 functioning primarily to degrade 
the enamel matrix in developing teeth.  
The role of KLK4 in the prostate, a tissue that highly 
expresses KLK4, is less clearly defined although it is 
thought to be important in prostate cancer progression 
given its role in degrading extracellular matrix (ECM) 
proteins in teeth, and potentially increasing IGF levels 
by degrading IGFBP3, IGFBP4, IGFBP5, IGFBP6. 
KLK4 is also reported to activate pro- HGFA and 
thereby potentially leading to tumour progression 
through activation of the MET receptor. A substrate 
specificity screening study has shown that full-length 
KLK4 has trypsin-like specificity and potentially 
activates proteins, such as, prostate specific antigen 
(PSA)/KLK3, bone morphogenetic protein (BMP) 
family and parathyroid hormone-related protein 
(PTHrP) that are involved in normal and neoplastic 
prostate (patho)-physiology. Recombinant KLK4 was 
also reported to be a better activator of PSA and single 
chain urokinase-type plasminogen activator than 
KLK2. More recently, KLK4 was shown to activate 
other members of the kallikrein-related peptidase 
family including KLK1, KLK2, KLK3, KLK5, KLK6, 
KLK9, KLK11, KLK12, KLK13, KLK14, KLK15. 
However, the precise physiological role for KLK4 in 
the prostate and other tissues remains to be identified. 
The function of the N-terminal truncated KLK4 
remains to be established. 
Homology 
At the protein level, KLK4 shares 25%, (KLK12), 29% 
(KLK10), 31% (KLK9), 34% (KLK1, 2, 3), 35% 
(KLK8, 13), 36% (KLK6), 37% (KLK15), 40% 
(KLK14), 43% (KLK7), 45% (KLK5) sequence 
homology with other members of the kallikrein-related 
peptidase family. Unlike KLK1, KLK2 and KLK3, 
KLK4 lacks the "kallikrein loop", a region of 11 amino 
acids encoded in exon 3 and thought to be important in 
the substrate  
specificity of these enzymes. KLK4 shares 72% 
sequence homology to the porcine EMPS1 protein. 
Bayesian phylogenetic analyses suggests that KLK4, 
KLK5 and KLK14 may form a sub-family within the 
kallikrein-related peptidase gene family. 
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Mutations 
Germinal 
A mutation in the KLK4 gene (G.2142>A) that encodes 
for a truncated KLK4 protein that lacks S207, which is 
necessary for catalytic activity, has been shown to 
associate with autosomal recessive hypomaturation 
amelogenesis imperfecta, which is a disorder affecting 
tooth enamel formation. Comparison of tooth enamel in 
patients with the G- and A-alleles suggest that wild-
type KLK4 (G allele) is important for the final removal 
of the extracellar enamel matrix proteins for normal 
enamel maturation. 
Implicated in 
Hormone dependent cancers 
Note 
It has been proposed that like PSA, encoded by the 
KLK3 gene, the KLK4 gene may play a role in 
hormone dependent cancers given its (a) higher 
expression in endocrine cells (b) regulation by 
hormones such as androgens, oestradiol and progestins 
(c) dysregulated expression in cancer cells and (d) 
potential role in extra-cellular matrix degradation and 
growth factor activation. 
Prostate cancer 
Note 
Hormone dependent cancer. 
Disease 
Kallikrein 4 has been reported to be more highly 
expressed in cancerous than benign prostate tissues at 
both the mRNA and protein levels. For example, a 
tissue microarray study carried out on 42 benign and 
207 malignant prostate tissues found that KLK4 was 
more highly expressed in prostate cancer cells when 
compared to benign cells, although one study using 
sandwich-type immunoassay on 16 malignant and 18 
benign prostate tissues found no difference in KLK4 
expression. It has also been shown that KLK4 specific 
antibodies can be detected in sera from prostate cancer 
patients. In prostate cancer cells, KLK4 has been 
shown to be up-regulated by androgens at both the 
mRNA and protein level. In two expression studies 
using Northern blot analysis, KLK4 mRNA expression 
was found to be up-regulated by 18- and 1.7 -fold after 
treatment of LNCaP cells with R1881 for 24 and 48 hr, 
respectively. Further, prostate cancer cells (PC-3 and 
DU145) transfected with KLK4 have also been shown 
to have increased cellular migration, proliferation and 
colony formation. Over-expression of KLK4 in prostate 
cancer cells has also been associated with increased 
migration of these cells to SaOs2 conditioned media 
and greater attachment to bone matrix proteins 
collagens I and IV. The role of KLK4 in prostate 
biology is thought to be mediated in part through 
activation of the PAR-1/F2R and PAR-2/F2RL1 
signalling pathways, although the precise mechanisms 
and importance in prostate cancer remain to be 
identified. 
Cytogenetics 
Comparison of two human prostate cell lines, 
P69SV40Tag (P69) and its tumorigenic subline, M12, 
and 11 prostate cancer cases showed LOH in M12 at 
19q13.42, which is proximal to the KLK4 locus. 
Hybrid/Mutated gene 
No KLK4 fusion transcript or protein has been reported 
thus far. 
Epithelial ovarian carcinoma 
Note 
Hormone dependent cancer. 
Disease 
Kallikrein 4 is more highly expressed in serous ovarian 
carcinomas at both the mRNA and protein levels, and 
high KLK4 mRNA expression is associated with 
poorly differentiated and late clinical stage ovarian 
carcinomas. KLK4 mRNA was also found to be 
expressed in tumour cells isolated from ascites fluid in 
60% (6/10) of ovarian cancer patients. KLK4 protein 
expression was also found to be more highly expressed 
in paclitaxel-resistant (79/93; 85%) than paclitaxel-
sensitive tumours (20/33; 61%), suggesting that KLK4 
may have utility as a predictive marker for 
chemoresistant ovarian cancers. Co-overexpression of 
KLK4, 5, 6 and 7 in ovarian cancer cells (OV-MZ-6) 
led to increased invasion in vitro and simultaneous 
expression of these KLKs in nude mice resulted in 
increased tumour burden. 
Prognosis 
KLK4 mRNA expression in tumour tissues indicates 
shorter overall and progression free survival time for 
epithelial ovarian carcinoma patients. It is also an 
independent indicator of poor prognosis in patients 
with grade 1 and 2 tumours. 
Breast cancer 
Note 
Hormone dependent cancer. 
Disease 
Comparison of RNA levels from normal and malignant 
breast tissue using real time RT-PCR showed that 
KLK4 expression was up-regulated in cancer cells. 
Further analysis using laser dissection of these tumours 
and immuno-histochemistry showed that the observed 
increase of KLK4 expression was due to increased 
expression in the surrounding stromal cells. 
Endometrial cancer 
Note 
Hormone dependent cancer. 
Disease 
KLK4 protein levels were shown by Western blot 
analysis to be up-regulated in endometrial KLE cells in 
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response to both oestradiol and progestin. This 
response was increased when cells were simultaneously 
treated with oestrogen and progesterone. 
Non-small cell lung cancer (NSCLC) 
Disease 
Using a KLK4 ELISA on 51 patients with NSCLC and 
50 normal controls, it was shown that KLK4 may have 
utility as a lung cancer biomarker when used in 
conjunction with KLK8, KLK10, KLK11, KLK12, 
KLK13, and KLK14. 
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